BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23376711)

  • 1. Role of the 5-HT₂A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice.
    Halberstadt AL; Powell SB; Geyer MA
    Neuropharmacology; 2013 Jul; 70():218-27. PubMed ID: 23376711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactive effects of mGlu5 and 5-HT2A receptors on locomotor activity in mice.
    Halberstadt AL; Lehmann-Masten VD; Geyer MA; Powell SB
    Psychopharmacology (Berl); 2011 May; 215(1):81-92. PubMed ID: 21153406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT₂A receptors, in mice.
    Fantegrossi WE; Gray BW; Bailey JM; Smith DA; Hansen M; Kristensen JL
    Psychopharmacology (Berl); 2015 Mar; 232(6):1039-47. PubMed ID: 25224567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice.
    Fantegrossi WE; Simoneau J; Cohen MS; Zimmerman SM; Henson CM; Rice KC; Woods JH
    J Pharmacol Exp Ther; 2010 Dec; 335(3):728-34. PubMed ID: 20858706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen.
    Halberstadt AL; van der Zee JVF; Chatha M; Geyer MA; Powell SB
    Psychopharmacology (Berl); 2019 Feb; 236(2):821-830. PubMed ID: 30448990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a hallucinogenic serotonin 5-HT
    Zhang G; Cinalli D; Stackman RW
    Hippocampus; 2017 May; 27(5):558-569. PubMed ID: 28176400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice.
    Halberstadt AL; Chatha M; Chapman SJ; Brandt SD
    J Psychopharmacol; 2019 Mar; 33(3):406-414. PubMed ID: 30789291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice.
    Halberstadt AL; van der Heijden I; Ruderman MA; Risbrough VB; Gingrich JA; Geyer MA; Powell SB
    Neuropsychopharmacology; 2009 Jul; 34(8):1958-67. PubMed ID: 19322172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model.
    Canal CE; Booth RG; Morgan D
    Neuropharmacology; 2013 Jul; 70():112-21. PubMed ID: 23353901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
    Marek GJ; Aghajanian GK
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.
    Halberstadt AL; Chatha M; Klein AK; Wallach J; Brandt SD
    Neuropharmacology; 2020 May; 167():107933. PubMed ID: 31917152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The serotonin 5-HT(2A) receptor agonist TCB-2: a behavioral and neurophysiological analysis.
    Fox MA; French HT; LaPorte JL; Blackler AR; Murphy DL
    Psychopharmacology (Berl); 2010 Sep; 212(1):13-23. PubMed ID: 19823806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic phenethylamine hallucinogen treatment alters behavioral sensitivity to a metabotropic glutamate 2/3 receptor agonist.
    Benneyworth MA; Smith RL; Sanders-Bush E
    Neuropsychopharmacology; 2008 Aug; 33(9):2206-16. PubMed ID: 17957214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.
    Borroto-Escuela DO; Romero-Fernandez W; Narvaez M; Oflijan J; Agnati LF; Fuxe K
    Biochem Biophys Res Commun; 2014 Jan; 443(1):278-84. PubMed ID: 24309097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonizing 5-HT₂A receptors with M100907 and stimulating 5-HT₂C receptors with Ro60-0175 blocks cocaine-induced locomotion and zif268 mRNA expression in Sprague-Dawley rats.
    Burton CL; Rizos Z; Diwan M; Nobrega JN; Fletcher PJ
    Behav Brain Res; 2013 Mar; 240():171-81. PubMed ID: 23201361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5HT-2 mediation of acute behavioral effects of hallucinogens in rats.
    Wing LL; Tapson GS; Geyer MA
    Psychopharmacology (Berl); 1990; 100(3):417-25. PubMed ID: 2138338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute serotonin 2A receptor activation impairs behavioral flexibility in mice.
    Amodeo DA; Hassan O; Klein L; Halberstadt AL; Powell SB
    Behav Brain Res; 2020 Oct; 395():112861. PubMed ID: 32814148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens.
    Halberstadt AL
    Curr Top Behav Neurosci; 2017; 32():283-311. PubMed ID: 28097528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TCB-2 [(7R)-3-bromo-2, 5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: A hallucinogenic drug, a selective 5-HT
    Di Giovanni G; De Deurwaerdère P
    Neuropharmacology; 2018 Nov; 142():20-29. PubMed ID: 28987938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors.
    Carlsson ML; Burstein ES; Kloberg A; Hansson S; Schedwin A; Nilsson M; Rung JP; Carlsson A
    J Neural Transm (Vienna); 2011 Nov; 118(11):1511-22. PubMed ID: 21874578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.